Rigel R&D Strategy Emphasizes Early Pipeline, Led By Asthma Drug
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Rigel’s focus on its early-stage projects for serious unmet medical needs overshadowed its Phase III rheumatoid arthritis candidate with AstraZeneca.